Drug companies must provide “unbiased information” to patients, say MEPs

BMJ 2010; 341 doi: 10.1136/bmj.c5511 (Published 5 October 2010)
Cite this as: BMJ 2010;341:c5511

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Rory Watson
  1. 1Brussels

Governments would have to ensure that “objective, unbiased information” about prescription drugs is made available to the public under legislation now being drafted by the European parliament.

The information would have to include a summary of product characteristics, the labelling and package leaflet, and a publicly accessible version of the drug’s assessment report. The data would have to be available electronically on dedicated websites established by national authorities and in printed form.

The obligation was introduced into the draft legislation last week by the European parliament’s environment committee as part of moves to provide …

Access to the full text of this article requires a subscription or payment

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

THIS WEEK'S POLL